Tolerability of BRAF/MEK Inhibitor Combinations: Adverse Event Evaluation and Management

ESMO Open - United Kingdom
doi 10.1136/esmoopen-2019-000491
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Systems Pharmacology of Adverse Event Mitigation by Drug Combinations

Science Translational Medicine
Medicine
2013English

Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma?

Oncology in Clinical Practice
Oncology
2019English

Trametinib: A MEK Inhibitor for Management of Metastatic Melanoma

OncoTargets and Therapy
OncologyPharmacology
2015English

PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors

Cancer Discovery
Oncology
2017English

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2012English

A Tolerability Burden Index in Schizophrenia: Incorporating Patient Perspective in Clinical Trial Adverse Event Reporting

Journal of Market Access & Health Policy
2017English

Management of Immune Checkpoint Inhibitor‐related Dermatologic Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

BRAF-Inhibitor Auch Langfristig Effektiv

Im Focus Onkologie
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy